LNCD(SH:600739) Sou Hu Cai Jing·2025-08-19 00:58Core Insights - The main business segments of the company include pharmaceuticals and healthcare, financial investment, supply chain services, and energy development, with steel products being the core revenue driver, accounting for 40.89% of total revenue [2] - The company has shown a significant increase in net profit over the years, achieving a net profit of 2.10 billion yuan in 2024, representing a cumulative growth of 378.84% since its listing in 1996 [2] - Despite the long-term growth in net profit, the company has experienced a decline in revenue, with a drop from 16.945 billion yuan in 2020 to 11.289 billion yuan in 2024 [2] - The company's market capitalization has increased 23.01 times since its listing, indicating long-term investment value, although it has seen a significant decrease from its peak market value of 59.305 billion yuan in 2007 to 19.351 billion yuan as of August 18, resulting in a market value loss of 67.37% [4] Financial Performance - The company has not reported any annual losses since its listing, with 13 years of net profit growth, representing 48.15% of the years since 1996 [2] - The net profit has seen a drastic decline from 2.771 billion yuan in 2020 to 210 million yuan in 2024, indicating a significant drop in profitability [2] - The revenue has shown a fluctuating downward trend in recent years, with the latest figures indicating a decrease in overall sales [2] Market Capitalization - The company’s market value peaked at 59.305 billion yuan in October 2007, with a corresponding stock price of 66.1 yuan [4] - As of August 18, the stock price was recorded at 12.65 yuan, reflecting a substantial decrease in market capitalization compared to its peak [4] - The overall market capitalization has decreased by 399.55 billion yuan from its peak, highlighting the volatility and challenges faced by the company in the market [4]